Novo Nordisk A/S Class B NONOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NONOF is a good fit for your portfolio.
News
-
Novo Nordisk Construction Site Hit by Fire
-
Novo Nordisk Partners With Metaphore Biotechnologies on New Obesity Drugs
-
FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal
-
Amgen 'very encouraged' by data from weight-loss-drug trial, as stock jumps
-
Novo Nordisk says starter doses of weight-loss drug surge as company hikes financial outlook
-
Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating — Update
-
Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating
-
Novo Holdings Set to Invest $200 Million in Quantum Technology
Trading Information
- Previous Close Price
- $133.98
- Day Range
- $128.05–135.00
- 52-Week Range
- $74.70–140.32
- Bid/Ask
- $128.05 / $135.00
- Market Cap
- $589.86 Bil
- Volume/Avg
- 4,537 / 26,434
Key Statistics
- Price/Earnings (Normalized)
- 45.72
- Price/Sales
- 16.71
- Dividend Yield (Trailing)
- 1.03%
- Dividend Yield (Forward)
- 0.20%
- Total Yield
- 1.71%
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 66,015
- Website
- https://www.novonordisk.com
Competitors
Valuation
Metric
|
NONOF
|
LLY
|
SNY
|
---|---|---|---|
Price/Earnings (Normalized) | 45.72 | 82.46 | 10.71 |
Price/Book Value | 41.29 | 57.20 | 1.60 |
Price/Sales | 16.71 | 19.39 | 2.42 |
Price/Cash Flow | 39.13 | 80.58 | 11.94 |
Price/Earnings
NONOF
LLY
SNY
Financial Strength
Metric
|
NONOF
|
LLY
|
SNY
|
---|---|---|---|
Quick Ratio | 0.49 | 0.68 | 0.83 |
Current Ratio | 0.70 | 1.35 | 1.27 |
Interest Coverage | 45.82 | 14.11 | 8.40 |
Quick Ratio
NONOF
LLY
SNY
Profitability
Metric
|
NONOF
|
LLY
|
SNY
|
---|---|---|---|
Return on Assets (Normalized) | 30.91% | 11.20% | — |
Return on Equity (Normalized) | 95.22% | 57.69% | — |
Return on Invested Capital (Normalized) | 73.76% | 20.65% | — |
Return on Assets
NONOF
LLY
SNY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xpbftmwf | Rfnq | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kdtstndkq | Vkrtrt | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ktdzzfhl | Hmcjvj | $108.2 Bil | |
MRNA
| Moderna Inc | Zvtctlrp | Glpss | $50.9 Bil | |
ARGX
| argenx SE ADR | Vprsgqbm | Dmcy | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Hssgfwhy | Jxlz | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zqlgqvmt | Rfpdn | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vcdvwqzr | Vnkwsqx | $14.6 Bil | |
INCY
| Incyte Corp | Lqswnqrk | Wqxcljx | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zdknjgbf | Zgjgfx | $12.3 Bil |